good potential company
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry.
Ind-Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its strength in organic synthetic chemistry resulted in the company emerging as the pioneer for a number of products both in the national and international markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it began establishing a presence in the highly regulated markets of the world.
To leverage its quality commitment, the Company has drawn out a long term strategy of emerging as a powerful force in the regulated markets as drugs worth over US$ 80 billion goes off patent during this decade.
Product range of the company include:
Macrolide antibiotics
Cardiovascular
Anti histamine
Anti diabetic
Analgesic
Aromatase inhibtors
Anti depressant
Alcohol absistence
MANUFACTURING
Manufacturing Facilities
1,50,000 sq. ft. covered area
5 Dedicated Blocks operating as per US FDA guidelines.
132 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 245 kilo liters)
3 Automated Fluidized Bed Coaters with capacity of manufacturing 3 MT of Granules per month.
cGMP Pilot Plant having 7 reaction vessels with capacities ranging from 250 to 1000 liters. (Total Volume 3.63 kilo liters)
Fully Automated Solvent Recovery System
Biological Waste Water Treatment Plant
Future plans
While development of new molecules will remain its core activity in the post patent era the Company will also focus on alternate and non-infringing routes for the drugs whose patent will expire in coming years.
To enter the regulated markets like USA, EU, Australia, and New Zealand, the company is focusing on getting its manufacturing plant approved by regulatory agencies like USFDA, TGA and MCA.
A new R&D Center with investment of $ 5 Million is already planned in Mohali with a focus to develop NCEs.
Ind-Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its strength in organic synthetic chemistry resulted in the company emerging as the pioneer for a number of products both in the national and international markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it began establishing a presence in the highly regulated markets of the world.
To leverage its quality commitment, the Company has drawn out a long term strategy of emerging as a powerful force in the regulated markets as drugs worth over US$ 80 billion goes off patent during this decade.
Product range of the company include:
Macrolide antibiotics
Cardiovascular
Anti histamine
Anti diabetic
Analgesic
Aromatase inhibtors
Anti depressant
Alcohol absistence
MANUFACTURING
Manufacturing Facilities
1,50,000 sq. ft. covered area
5 Dedicated Blocks operating as per US FDA guidelines.
132 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 245 kilo liters)
3 Automated Fluidized Bed Coaters with capacity of manufacturing 3 MT of Granules per month.
cGMP Pilot Plant having 7 reaction vessels with capacities ranging from 250 to 1000 liters. (Total Volume 3.63 kilo liters)
Fully Automated Solvent Recovery System
Biological Waste Water Treatment Plant
Future plans
While development of new molecules will remain its core activity in the post patent era the Company will also focus on alternate and non-infringing routes for the drugs whose patent will expire in coming years.
To enter the regulated markets like USA, EU, Australia, and New Zealand, the company is focusing on getting its manufacturing plant approved by regulatory agencies like USFDA, TGA and MCA.
A new R&D Center with investment of $ 5 Million is already planned in Mohali with a focus to develop NCEs.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.